الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 115 |  |  |
| | | from | 115 | | |
Abstract
Periprocedural myocardial infarction and injury (PM-injury) are the most common complications of percutaneous coronary intervention (PCI) and are associated with future adverse cardiac events. Colchicine is a cheap and effective drug, well-known to manage a vast array of diseases. It has been demonstrated that; colchicine recorded talented outcomes with regard to the reduction in the possibility of recurrent myocardial infarction (MI), stroke, and sudden cardiac arrest, playing a major role in lowering inflammation and the mortality caused by cardiovascular diseases (CVD). The aim of the current study was to evaluate the effect of colchicine intake on short term outcome of elective percutaneous coronary intervention in chronic ischemic heart disease. This was a prospective randomized, double-blind, placebo controlled trial conducted to determine the effects of acute preprocedural oral administration of 1.5 mg of colchicine on PCI-related myocardial injury. In our study we have basal troponin level Preprocedural and the postprocedural troponin level is classified to 3 groups; Myocardial minor injury : Elevated postprocedural troponin level but less than five folds of basal troponin with no signs nor symptoms of new myocardial ischemia, Myocardial Major injury : Elevated postprocedural troponin level more than five folds of basal troponin , but with no signs nor symptoms of new myocardial ischemia and myocardial Infarction : Elevated postprocedural troponin level more than five folds of basal troponin , with signs and symptoms of new myocardial ischemia like new ischemic ECG changes or new wall motion abnormalities. The current study revealed the following: No significant differences were recorded between both groups regarding all demographic data and clinical examination. •No significant difference was recorded between group B and group A regarding MACE. •Non-significant difference was recorded between the studied groups as regard pre-procedural ECG findings with 62% of each of the studied groups have abnormal findings. •There was a statistically significant higher frequency of abnormal ECG findings between group B than group A, while comparing pre and post-procedural ECG changes demonstrated statistically significant change for group A only from 62 to 46%. •For pre-procedural assessment a non-statistically significant difference between studied groups is detected as regard; CRP and serum creatinine. •Post procedural CRP and creatinine demonstrated statistically significant difference between studied groups, while comparing pre and post procedural value ; a statistically significant increase creatinine and decrease in CRP was detected for each of the studied groups. •Non-statistically significant difference was recorded between studied groups as regard troponin change pre and postprocedural with higher frequency of myocardial minor, major injury and infarction was detected among control than intervention group. •Significant difference was recorded between studied groups as regard PCI. Successful PCI to RCA is more frequent among group B than A and successful PCI to LCX. More frequent among group A than B successful PCI to LAD. Conclusion:Adding colchicine to standard medical therapy in patients undergoing PCI 1-2 hours before the procedure did not decrease MACE, and as regard to major and minor myocardial injury and myocardial infarction post PCI there was non-statistically significant changes between the two groups. However, it showed a trend towards a lower risk of increasing inflammatory markers post PCI. As regard to ECG ischemic changes, there were significant changes between both groups.